Withdrawal of MMF may be safely in #SLE patients in remission #ACR20 @RheumNow Dr Chakravarty https://t.co/xnpagKNu96

Dr Joan Merrill presents a phase 2 trial use of Iberdomide in patients with #SLE -Novel MOA —> blocks TF Ailos and Ikaros Conclusion -Primary end point was met at week 24 -Effects greater in Aiolos high/Type 2 IFN high -Iverdomdie was tolerated well #Lupus #ACR20 #ACRambassador https://t.co/zpQR9ceV7p

Dr Richard Furie-> Obinutuzumab for proliferative #lupus nephritis -Compared to rituximab, has more B-cell depletion in tissue and #SLE patients -Meaningful benefits over SOC alone on renal response through week 104. -Phase 3 REGENCY pending. #ACR20 #ACRambassador #Rheumatology https://t.co/aPi1yueAiV

Can’t a clinician usually differentiate dermatomysitis skin changes from cutaneous lupus and if not would it affect your Rx of the skin involvement - HCQ, MMF, MTX, Aza & topicals. IL18 sigatures. But I get it. Impt for pathogenesis! @RheumNow #ACR2020 @CRASCRRheum https://t.co/RJh7fEVo4O

• https://twitter.com/rayzuomd/status/1325120875058896896

@andreafava representing @jhrheumatology @HopkinsBayview at plenary session! Urine proteomic biomarkers can revolutionize the way we see LN, and decrease need for renal Bx #Acr20 @RheumNow Abst#0936 https://t.co/zGoqmBPddT

Can we use urine testing ( and all the cells, proteins, complements, DNA, rna) to predict LN response? Plenary II @SalemAlmaani @BradRovin @RheumNow #ACR20 @OSUWexMed

Great talk #ACR20 Integrating bulk and single-cell RNA-sequencing @Kahlenberglab identifies clinically actionable 5-gene signatures that can effectively differentiate DM from cutaneous lupus lesions. @RheumNow @UMIntMed Also out in @JCI_insight https://t.co/uYS6OJH0Hf https://t.co/KR0wwDb5BK

• JCI Insight - IL18-containing 5-gene signature distinguishes histologically id…

50% use septra/bactrim in SLE if immunesuppressed. I don’t use it unless if frequent serious infections or bad lungs as I am not convinced about the risk of PCP/PJP v risk of septra with adverse rxns in SLE. I await an admin database to give me the data @RheumNow #ACR20 https://t.co/3s2S9fIUVe

Dr. Aggarwal Abs#0955 showed efficacy of IVIG in tx of Dermatomyositis. How/when do you use IVIG for tx of DM? @RheumNow #ACR20

Efficacy of IVIG in Dermatomyositis Treatment 1st Placebo controlled RCT 1️⃣79% responder by total improvement score vs. 44% 2️⃣Efficacy sustained thru wk 40 3️⃣6% serious AE - thromboembolic event @RheumNow #ACR20 Abs#0955 #ACRbest https://t.co/715h1UkZ9X